Comparative Pharmacology
Head-to-head clinical analysis: ALESSE versus PREMPHASE 14 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALESSE versus PREMPHASE 14 14.
ALESSE vs PREMPHASE 14/14
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Conjugated estrogens (CE) bind to estrogen receptors (ERα and ERβ), modulating gene transcription and non-genomic signaling pathways to induce estrogenic effects. Medroxyprogesterone acetate (MPA) is a progestin that binds to progesterone receptors, suppressing endometrial proliferation and counteracting estrogen-induced endometrial hyperplasia. The combination provides hormone replacement therapy with reduced risk of endometrial cancer.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
One tablet orally once daily, each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg.
None Documented
None Documented
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Conjugated estrogens have a terminal elimination half-life of 12-24 hours for conjugated equine estrogens; medroxyprogesterone acetate has a half-life of 12-17 hours. Steady-state is reached within 5-7 days.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Conjugated estrogens are excreted primarily in urine (≥90%) as glucuronide and sulfate conjugates; medroxyprogesterone acetate is extensively metabolized and excreted in urine (≤60%) and feces (≤30%) as metabolites.
Category C
Category C
Estrogen/Progestin Combination Contraceptive
Estrogen/Progestin Combination